Review



bufalin  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    MedChemExpress bufalin
    Bufalin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 18 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n0877/Bufalin/pmc12776075-54-0-5
    Average 94 stars, based on 18 article reviews
    bufalin - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    Binding Assay:

    Article Title: Bufalin reverses oxaliplatin resistance in gastric cancer by targeting YBX1 to suppress glycolysis.
    Article Snippet: Oxaliplatin resistance is a key challenge in gastric cancer therapy.. This study explored how bufalin, an active component of Chansu, reverses this resistance.. We found that bufalin targets the transcription factor YBX1, which is upregulated in resistant cells.

    other:

    Article Title: Bufalin: a potential drug for regulating EGFR-TKIs resistance in lung cancer via the EGFR-PI3K/Akt-mTOR signaling
    Article Snippet: Bufalin was obtained from the MedChemExpress (HY-N0877, Monmouth Junction, NJ, USA).

    CCK-8 Assay:

    Article Title: Bufalin reverses oxaliplatin resistance in gastric cancer by targeting YBX1 to suppress glycolysis.
    Article Snippet: Oxaliplatin resistance is a key challenge in gastric cancer therapy.. This study explored how bufalin, an active component of Chansu, reverses this resistance.. We found that bufalin targets the transcription factor YBX1, which is upregulated in resistant cells.



    Similar Products

    94
    MedChemExpress intervention with bufalin
    Inhibition of ferroptosis is central to <t>bufalin-mediated</t> protection against TIF. (a) GSH levels in db/db mice. (b and c) RT–qPCR and Western blot analysis of ferroptosis-related indicators were performed to evaluate the role of bufalin in ferroptosis in DKD mice. (d, e, and f) The cellular contents of GSH, Fe 2+ and MDA verified the role of bufalin in ferroptosis. (g and h) The inhibitory effect of bufalin on ferroptosis in HG-treated RTECs was demonstrated by RT–qPCR and Western blot. (i) ROS levels in bufalin-treated RTECs. (j) TEM revealed mitigated mitochondrial changes after the intervention of bufalin. The scale bar is located at the bottom of the image. (k and l) The expression changes of TIF-related indicators after co-treatment <t>with</t> <t>bufalin</t> and Fer-1 were detected by RT-qPCR and Western blot. For in vivo experiments, n = 6 per group; for cellular experiments, n = 4. The data are expressed as the mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, # p < 0.05, ## p < 0.01, ### p < 0.001 vs. the indicated group. NS, non-significant.
    Intervention With Bufalin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n0877/Bufalin/pmc13215403-35-0-4
    Average 94 stars, based on 1 article reviews
    intervention with bufalin - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress bufalin
    Inhibition of ferroptosis is central to <t>bufalin-mediated</t> protection against TIF. (a) GSH levels in db/db mice. (b and c) RT–qPCR and Western blot analysis of ferroptosis-related indicators were performed to evaluate the role of bufalin in ferroptosis in DKD mice. (d, e, and f) The cellular contents of GSH, Fe 2+ and MDA verified the role of bufalin in ferroptosis. (g and h) The inhibitory effect of bufalin on ferroptosis in HG-treated RTECs was demonstrated by RT–qPCR and Western blot. (i) ROS levels in bufalin-treated RTECs. (j) TEM revealed mitigated mitochondrial changes after the intervention of bufalin. The scale bar is located at the bottom of the image. (k and l) The expression changes of TIF-related indicators after co-treatment <t>with</t> <t>bufalin</t> and Fer-1 were detected by RT-qPCR and Western blot. For in vivo experiments, n = 6 per group; for cellular experiments, n = 4. The data are expressed as the mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, # p < 0.05, ## p < 0.01, ### p < 0.001 vs. the indicated group. NS, non-significant.
    Bufalin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n0877/Bufalin/pm41991006-152-14-16
    Average 94 stars, based on 1 article reviews
    bufalin - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress hy n0877
    Inhibition of ferroptosis is central to <t>bufalin-mediated</t> protection against TIF. (a) GSH levels in db/db mice. (b and c) RT–qPCR and Western blot analysis of ferroptosis-related indicators were performed to evaluate the role of bufalin in ferroptosis in DKD mice. (d, e, and f) The cellular contents of GSH, Fe 2+ and MDA verified the role of bufalin in ferroptosis. (g and h) The inhibitory effect of bufalin on ferroptosis in HG-treated RTECs was demonstrated by RT–qPCR and Western blot. (i) ROS levels in bufalin-treated RTECs. (j) TEM revealed mitigated mitochondrial changes after the intervention of bufalin. The scale bar is located at the bottom of the image. (k and l) The expression changes of TIF-related indicators after co-treatment <t>with</t> <t>bufalin</t> and Fer-1 were detected by RT-qPCR and Western blot. For in vivo experiments, n = 6 per group; for cellular experiments, n = 4. The data are expressed as the mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, # p < 0.05, ## p < 0.01, ### p < 0.001 vs. the indicated group. NS, non-significant.
    Hy N0877, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n0877/Bufalin/pmc12776075-54-6-5
    Average 94 stars, based on 1 article reviews
    hy n0877 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    Image Search Results


    Inhibition of ferroptosis is central to bufalin-mediated protection against TIF. (a) GSH levels in db/db mice. (b and c) RT–qPCR and Western blot analysis of ferroptosis-related indicators were performed to evaluate the role of bufalin in ferroptosis in DKD mice. (d, e, and f) The cellular contents of GSH, Fe 2+ and MDA verified the role of bufalin in ferroptosis. (g and h) The inhibitory effect of bufalin on ferroptosis in HG-treated RTECs was demonstrated by RT–qPCR and Western blot. (i) ROS levels in bufalin-treated RTECs. (j) TEM revealed mitigated mitochondrial changes after the intervention of bufalin. The scale bar is located at the bottom of the image. (k and l) The expression changes of TIF-related indicators after co-treatment with bufalin and Fer-1 were detected by RT-qPCR and Western blot. For in vivo experiments, n = 6 per group; for cellular experiments, n = 4. The data are expressed as the mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, # p < 0.05, ## p < 0.01, ### p < 0.001 vs. the indicated group. NS, non-significant.

    Journal: Renal Failure

    Article Title: Bufalin post-transcriptionally suppresses STAT3 to alleviate renal ferroptosis and tubulointerstitial fibrosis in diabetic kidney disease

    doi: 10.1080/0886022X.2026.2667591

    Figure Lengend Snippet: Inhibition of ferroptosis is central to bufalin-mediated protection against TIF. (a) GSH levels in db/db mice. (b and c) RT–qPCR and Western blot analysis of ferroptosis-related indicators were performed to evaluate the role of bufalin in ferroptosis in DKD mice. (d, e, and f) The cellular contents of GSH, Fe 2+ and MDA verified the role of bufalin in ferroptosis. (g and h) The inhibitory effect of bufalin on ferroptosis in HG-treated RTECs was demonstrated by RT–qPCR and Western blot. (i) ROS levels in bufalin-treated RTECs. (j) TEM revealed mitigated mitochondrial changes after the intervention of bufalin. The scale bar is located at the bottom of the image. (k and l) The expression changes of TIF-related indicators after co-treatment with bufalin and Fer-1 were detected by RT-qPCR and Western blot. For in vivo experiments, n = 6 per group; for cellular experiments, n = 4. The data are expressed as the mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, # p < 0.05, ## p < 0.01, ### p < 0.001 vs. the indicated group. NS, non-significant.

    Article Snippet: Intervention with bufalin (HY-N0877R, MCE, Monmouth Junction, USA) and Fer-1 (HY-100579, MCE, Monmouth Junction, USA) was performed when the mice were 12 weeks old.

    Techniques: Inhibition, Quantitative RT-PCR, Western Blot, Expressing, In Vivo

    Bufalin downregulates STAT3 via post-transcriptional regulation. (a) The binding sites of bufalin and STAT3 that could be interacted with were predicted by molecular docking method. The binding sites, conformations, and docking scores are presented here. (b) In RTECs pretreated with bufalin, STAT3 overexpression plasmid or STAT3 siRNA were respectively transfected. The protein expression levels of ferroptosis and TIF-related indicators were detected by Western blot. (c) The expression changes of STAT3 in the kidney tissues of mice treated with bufalin were detected by IHC. Scale bar, 50 μm. (d) RT-qPCR was used to detect the mRNA expression level of STAT3 under the intervention of bufalin. (e) Detection and ratio analysis of STAT3 precursor mRNA and mature mRNA expression. (f) The binding of bufalin and STAT3 3′ UTR was verified by dual-luciferase reporter assay. (g) The mRNA stability of STAT3 in RTECs treated with bufalin was significantly decreased. For in vivo experiments, n = 6 per group; for cellular experiments, n = 4. The data are expressed as the mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, # p < 0.05 vs. the indicated group. NS, non-significant.

    Journal: Renal Failure

    Article Title: Bufalin post-transcriptionally suppresses STAT3 to alleviate renal ferroptosis and tubulointerstitial fibrosis in diabetic kidney disease

    doi: 10.1080/0886022X.2026.2667591

    Figure Lengend Snippet: Bufalin downregulates STAT3 via post-transcriptional regulation. (a) The binding sites of bufalin and STAT3 that could be interacted with were predicted by molecular docking method. The binding sites, conformations, and docking scores are presented here. (b) In RTECs pretreated with bufalin, STAT3 overexpression plasmid or STAT3 siRNA were respectively transfected. The protein expression levels of ferroptosis and TIF-related indicators were detected by Western blot. (c) The expression changes of STAT3 in the kidney tissues of mice treated with bufalin were detected by IHC. Scale bar, 50 μm. (d) RT-qPCR was used to detect the mRNA expression level of STAT3 under the intervention of bufalin. (e) Detection and ratio analysis of STAT3 precursor mRNA and mature mRNA expression. (f) The binding of bufalin and STAT3 3′ UTR was verified by dual-luciferase reporter assay. (g) The mRNA stability of STAT3 in RTECs treated with bufalin was significantly decreased. For in vivo experiments, n = 6 per group; for cellular experiments, n = 4. The data are expressed as the mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, # p < 0.05 vs. the indicated group. NS, non-significant.

    Article Snippet: Intervention with bufalin (HY-N0877R, MCE, Monmouth Junction, USA) and Fer-1 (HY-100579, MCE, Monmouth Junction, USA) was performed when the mice were 12 weeks old.

    Techniques: Binding Assay, Over Expression, Plasmid Preparation, Transfection, Expressing, Western Blot, Quantitative RT-PCR, Luciferase, Reporter Assay, In Vivo